Equities Analysts Set Expectations for PHIO Q3 Earnings

Phio Pharmaceuticals Corp. (NASDAQ:PHIO) – Sidoti cut their Q3 2026 earnings per share estimates for Phio Pharmaceuticals in a report issued on Friday, August 7th. Sidoti analyst A. Hantman now anticipates that the company will earn ($0.35) per share for the quarter, down from their previous forecast of ($0.31). The consensus estimate for Phio Pharmaceuticals’ current full-year earnings is ($1.38) per share. Sidoti also issued estimates for Phio Pharmaceuticals’ Q4 2026 earnings at ($0.37) EPS, FY2026 earnings at ($1.42) EPS, Q1 2027 earnings at ($0.13) EPS, Q2 2027 earnings at ($0.09) EPS, Q3 2027 earnings at ($0.11) EPS, Q4 2027 earnings at ($0.13) EPS and FY2027 earnings at ($0.45) EPS.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Phio Pharmaceuticals in a research report on Friday, July 17th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $14.00.

Phio Pharmaceuticals Stock Up 1.9%

Shares of PHIO opened at $1.06 on Tuesday. The business’s 50-day moving average price is $1.04 and its 200-day moving average price is $1.12. Phio Pharmaceuticals has a twelve month low of $0.81 and a twelve month high of $4.19. The stock has a market cap of $12.32 million, a PE ratio of -0.82 and a beta of 0.82.

Phio Pharmaceuticals (NASDAQ:PHIO) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.36) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.36).

Institutional Inflows and Outflows

An institutional investor recently raised its position in Phio Pharmaceuticals stock. Geode Capital Management LLC lifted its position in Phio Pharmaceuticals Corp. (NASDAQ:PHIO) by 60.0% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 92,638 shares of the company’s stock after purchasing an additional 34,732 shares during the quarter. Geode Capital Management LLC owned 0.86% of Phio Pharmaceuticals worth $97,000 at the end of the most recent quarter. 57.31% of the stock is owned by institutional investors.

About Phio Pharmaceuticals

Phio Pharmaceuticals, Inc (NASDAQ: PHIO) is a clinical‐stage biotechnology company focused on the discovery and development of dual RNA interference (RNAi) therapeutics. Utilizing its proprietary Transitional RNAi (TRiMTM) platform, Phio aims to simultaneously silence multiple gene targets to achieve enhanced therapeutic activity. The company’s core mission is to advance next‐generation RNAi compounds with potential applications in oncology and immuno‐oncology.

Phio’s TRiMTM platform is designed around the delivery of synthetic, double‐stranded RNA duplexes that can be engineered to target specific combinations of genes implicated in tumor growth and immune evasion.